Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 6/2010

01-06-2010 | Gastrointestinal Oncology

Chemoradiotherapy in Adenocarcinoma of the Stomach or Esophagus

Authors: Christof Hottenrott, MD, Dimosthenis Ziogas, MD

Published in: Annals of Surgical Oncology | Issue 6/2010

Login to get access

Excerpt

Adjuvant postoperative chemoradiotherapy has been the standard of care for adenocarcinoma of the stomach and esophagogastric junction in the United States. This recommendation is based on the positive results of a phase III randomized controlled trial (INT-0116). However, the extent of surgery with limited D0 or D1 lymphadenectomy in this study has been criticized. This treatment modality has not been adopted as standard approach in Japan and Europe. It is though that better locoregional tumor control and improved distant recurrence can be achieved with D2 surgery and postoperative adjuvant chemotherapy or surgery plus perioperative chemotherapy. …
Literature
1.
Solomon NL, Cheung MC, Byrne MM, et al. Does chemoradiotherapy improve outcomes for surgically resected adenocarcinoma of the stomach or esophagus? Ann Surg Oncol. 2010;17:98–108.CrossRefPubMed
2.
Roukos DH. Genome-wide association studies and aggressive surgery toward individualized prevention, and improved local control and overall survival for gastric cancer. Ann Surg Oncol. 2009;16:795–8.CrossRefPubMed
3.
4.
Roukos DH. Mea culpa with cancer-targeted therapy: new thinking and new agents design for novel, causal networks-based, personalized biomedicine. Expert Rev Mol Diagn. 2009;93:217–21.CrossRef
5.
Roukos DH. Genome-wide association studies: how predictable is a person’s cancer risk? Expert Rev Anticancer Ther. 2009;9:389–92.CrossRefPubMed
6.
Roukos DH. Systems medicine: a real approach for future personalized oncology? Pharmacogenomics 2010;11(3):283–7.CrossRefPubMed
7.
Roukos DH, Ziogas D. From tumor size and HER2 status to systems oncology for very early breast cancer treatment. Expert Rev Anticancer Ther. 2010;10(2):123–8.CrossRefPubMed
8.
Roukos DH. Novel clinico-genome network modeling for revolutionizing genotype-phenotype-based personalized cancer care. Expert Rev Mol Diagn. 2010;10(1):33–48.CrossRefPubMed
9.
10.
Roukos DH, Tzakos A, Zografos G. Current concerns and challenges towards tailored anti-angiogenic therapy in cancer. Expert Rev Anticancer Ther. 2009;9(10):1413–6.CrossRefPubMed
11.
Ziogas D, Roukos DH. Genetics and personal genomics for personalized breast cancer surgery: progress and challenges in research and clinical practice. Ann Surg Oncol. 2009;16(7):1771–82.CrossRefPubMed
12.
Roukos DH. Targeting gastric cancer with trastuzumab: new clinical practice and innovative developments to overcome resistance. Ann Surg Oncol. 2010;17:14–7.CrossRefPubMed
Metadata
Title
Chemoradiotherapy in Adenocarcinoma of the Stomach or Esophagus
Authors
Christof Hottenrott, MD
Dimosthenis Ziogas, MD
Publication date
01-06-2010
Publisher
Springer-Verlag
Published in
Annals of Surgical Oncology / Issue 6/2010
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-010-1013-4

Other articles of this Issue 6/2010

Annals of Surgical Oncology 6/2010 Go to the issue

Reconstructive Oncology

Skin-Sparing Mastectomy and Immediate Breast Reconstruction in the Management of Locally Recurrent Breast Cancer

Endocrine Tumors

New Operative Surgical Concept of Two Fascial Layers Enveloping the Recurrent Laryngeal Nerve

Breast Oncology

HER-2-Negative Breast Cancer Limitations and Next-Generation Sequencing Technology Promises

Gastrointestinal Oncology

In Reply: Does Metastatic Lymph Node Ratio Really Suit for Prognostic Prediction of the D1 Lymphadenectomy?

Gastrointestinal Oncology

Does Metastatic Lymph Node Ratio Really Suit for Prognostic Prediction of the D1 Lymphadenectomy?

Breast Oncology

Changes in Circulating Tumor Cell Detection in Patients with Localized Breast Cancer Before and After Surgery